Amneal Pharmaceuticals (AMRX) Interest Expenses (2017 - 2026)

Amneal Pharmaceuticals' Interest Expenses history runs 10 years deep, the most recent figure standing at $117.7 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 27.44% year-over-year to $117.7 million in Q1 2026; TTM through Mar 2026 was $117.7 million, a 27.44% increase from a year earlier, with the FY2025 full-year figure at $586.6 million, down 0.63% from the prior year.
• Interest Expenses rose to $117.7 million in Q1 2026 per AMRX's latest filing, from $41.4 million in the prior quarter.
• Across five years, Interest Expenses topped out at $566.0 million in Q1 2024 and bottomed at -$193.7 million in Q4 2024.
• The 5-year median for Interest Expenses is $85.9 million (2025), against an average of $181.7 million.
• Across the five-year window, Interest Expenses soared 578.63% in 2023 and slumped 444.65% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $50.5 million in 2022, then climbed by 11.28% to $56.2 million in 2023, then slumped by 444.65% to -$193.7 million in 2024, then surged by 121.37% to $41.4 million in 2025, then jumped by 184.39% to $117.7 million in 2026.
• Per Business Quant, the three latest AMRX Interest Expenses figures stand at $117.7 million (Q1 2026), $41.4 million (Q4 2025), and $126.3 million (Q3 2025).